Collin D'Silva has resigned from Bruker's audit committee to become the president of the newly formed Chemical Analysis division of Bruker Daltonics, the company said in documents filed with the US Securities and Exchange Commission this past week.
As a result, Bruker said that it is no longer in compliance with Nasdaq requirements that a company's audit committee have at least three members. The company said that it received notice from the exchange of its non-compliance this week.
Bruker has 180 days, or until Sept. 27, from D'Silva's resignation date, March 9, to regain compliance. The company said in its filing that it plans to fill the vacancy "as expeditiously as possible" before the deadline.
D'Silva remains an independent director of Bruker.
He was CEO of Transgenomic from 1997 to 2006, and was previously founder, president, and CEO of CETAC Technologies.
Integrated Diagnostics this week announced the appointment of Albert Luderer as its CEO.
Luderer has more than 30 years of experience in biotechnology and was previously CEO of BioTrove, which was acquired by Life Technologies in December. Before that, he was CEO of therapeutics firm Light Sciences, and president and chief operating officer of BioMérieux.
Integrated Diagnostics was co-founded last fall by Lee Hood to use proteomics and genomics technologies to leverage previously discovered biomarkers and develop diagnostics based on them for a broad range of diseases. The company raised $30 million in Series A financing (PM 10/16/09).
Proteros last week announced the formation of its board of directors.
Timm Jessen will serve as chairman. He is the managing partner of Bionamics and was the chief scientific officer of Evotec. He also has held various positions at Sanofi Aventis.
Dave Lemus, chief financial officer of MorphoSys, is serving as deputy chairman, while Robert Huber, co-founder of Proteros and the co-recipient of the Nobel Prize in Chemistry in 1988, was appointed honorary president.
The other board members are Ingo Köhler, CEO of Viscon; Berthold Hinzen, head of global business development and licensing for general medicine at Bayer-Schering Pharma; and Andre Schmutte, a Six Sigma management consultant.